Abstract: Crystalline form of the p38 kinase inhibitor 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyra-zol-5-yl]piperidin-1-yl}-2-oxoethanol can be used, is provided. The crystalline form is a hydrated crystalline form. Also provided are combinations and pharmaceutical compositions comprising the crystalline form, process for preparing the crystalline form and for preparing compositions comprising the crystalline form, in methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline form of 1.

Abstract: The present invention relates to amidino compounds and salts and prodrugs thereof. In another embodiment the present invention also provides a use of the present compounds in therapy, particular as nitric oxide synthase inhibitors. In a further embodiment, the present invention provides methods of making the amidino compounds.

Abstract: A parenterally deliverable pharmaceutical composition comprises a water soluble parecoxib salt, in dissolved and/or solubilized form in a solvent liquid that comprises water and one or more nonaqueous solubilizer(s). Valdecoxib formed by conversion of parecoxib is solubilized by the nonaqueous solubilizer(s), which are substantially inert with respect to such conversion. The composition has parecoxib salt stabilizing means for inhibiting precipitation of parecoxib free acid. The composition is storage stable and is suitable for parenteral administration to treat a COX-2 mediated condition or disorder.